Aspire Biopharma, Inc. (NASDAQ:PWUP) | WebDisclosure

Switch to English

9804	Sociétés
196637	Mots-clés
127655	Articles
104547	Communiqués

Accueil
Sociétés
Aspire Biopharma, Inc.

COMMUNIQUÉ DE PRESSE

publié le 10/06/2025 à 14:30, il y a 7 mois 24 jours

Aspire Biopharma Holdings, Inc., Announces Michael C. Howe - With Decades of Experience at Leading and Building Brands in the Healthcare and Consumer Space - To Be Its New Chief Executive Officer
Michael Howe to become CEO of Aspire Biopharma Holdings, Inc. on June 10, 2025. His extensive career in leading brands and early-stage companies makes him a strategic fit for the role

Healthcare Board Member CEO Michael Howe Aspire Biopharma Holdings, Inc.
BRÈVE

publiée le 28/05/2025 à 14:35, il y a 8 mois 7 jours

Aspire Biopharma dévoile BUZZ BOMB™ : une nouvelle ère dans les compléments pré-entraînement

Technologie Sublinguale Marché Du Fitness Supplément Pré-entraînement BUZZ BOMB™ Livraison De Caféine
BRÈVE

publiée le 28/05/2025 à 14:35, il y a 8 mois 7 jours

Aspire Biopharma Unveils BUZZ BOMB™: A New Era in Pre-Workout Supplements

Sublingual Technology Fitness Market Pre-workout Supplement BUZZ BOMB™ Caffeine Delivery
COMMUNIQUÉ DE PRESSE

publié le 28/05/2025 à 14:30, il y a 8 mois 7 jours

Aspire Biopharma Holdings, Inc., Provides Development Update on BUZZ BOMB(TM), its New Sublingual Pre-Workout Supplement, Expected to Launch in Third Quarter of 2025
Aspire Biopharma introduces BUZZ BOMB™, a sublingual pre-workout supplement delivering rapid caffeine to support athletes' performance. Six flavors available in convenient single servings. Global pre-workout supplements market on the rise

Aspire Biopharma Pre-workout Supplement Sublingual BUZZ BOMB™ Caffeine
BRÈVE

publiée le 20/05/2025 à 14:35, il y a 8 mois 15 jours

Aspire Biopharma lance un essai de phase 1 sur une formulation d'aspirine à haute dose

Développement Clinique Examen De La FDA Essai De Phase 1 Aspirine À Haute Dose Absorption Sublinguale
BRÈVE

publiée le 20/05/2025 à 14:35, il y a 8 mois 15 jours

Aspire Biopharma Begins Phase 1 Trial of High-Dose Aspirin Formulation

Clinical Development Phase 1 Trial FDA Review High-dose Aspirin Sublingual Absorption
COMMUNIQUÉ DE PRESSE

publié le 20/05/2025 à 14:30, il y a 8 mois 15 jours

Aspire Biopharma Holdings, Inc., Announces First Patient Dosed in Phase 1 Clinical Trial for its Lead Program, an Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation
Aspire Biopharma initiates Phase 1 trial for high-dose aspirin formulation in the United States, targeting accelerated approval with positive data anticipated in 3Q 2025

Accelerated Approval Phase 1 Trial FDA Feedback Aspire Biopharma High-dose Aspirin Formulation
BRÈVE

publiée le 08/05/2025 à 14:05, il y a 8 mois 27 jours

Aspire Biopharma to Participate in Sidoti Virtual Investor Conference

Investor Presentation Drug Delivery Technology Sidoti Conference Aspire Biopharma Virtual Meetings
BRÈVE

publiée le 08/05/2025 à 14:05, il y a 8 mois 27 jours

Aspire Biopharma participera à la conférence virtuelle des investisseurs de Sidoti

Presentation Aux Investisseurs Technologie D'administration De Médicaments Conférence De Sidoti Aspire Biopharma Réunions Virtuelles
COMMUNIQUÉ DE PRESSE

publié le 08/05/2025 à 14:00, il y a 8 mois 27 jours

Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference May 21
Aspire Biopharma to present at Sidoti Virtual Investor Conference on May 21 and host virtual one-on-ones with investors. Company's disruptive drug delivery technology highlighted

Sidoti Virtual Investor Conference Virtual Presentation One-on-one Meetings Drug Delivery Technology Aspire Biopharma

Les Echos

Publié le 04/02/2026 à 18:04, il y a 6 heures 33 minutes

Capital et droits de vote au 31 janvier 2026
Publié le 04/02/2026 à 18:04, il y a 6 heures 33 minutes

Total number of voting rights and shares making up the share capital at January 31, 2026
Publié le 04/02/2026 à 17:45, il y a 6 heures 52 minutes

Information concerning the total number of voting rights and shares 2026 01 31
Publié le 04/02/2026 à 17:45, il y a 6 heures 52 minutes

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Publié le 04/02/2026 à 17:45, il y a 6 heures 52 minutes

Janvier 2026

Voir tout LES ECHOS COMFI WIRE

Accesswire

Publié le 05/02/2026 à 00:00, il y a 37 minutes

Onco-Innovations Announces Filing of Preliminary Base Shelf Prospectus
Publié le 04/02/2026 à 22:25, il y a 2 heures 12 minutes

55 North Mining Announces Flow-Through Financing
Publié le 04/02/2026 à 18:00, il y a 6 heures 37 minutes

Lithium South AGSM Update
Publié le 04/02/2026 à 16:15, il y a 8 heures 22 minutes

Trans Canada Gold Enters into an Option Agreement with Bear Mountain Gold Mines to Acquire a 60% Interest in the Harrison Lake District Scale Gold Property, with $10.0 Million Dollars in Prior Exploration Expenditures
Publié le 04/02/2026 à 15:45, il y a 8 heures 52 minutes

Patriot.Tv's Jd Rucker Explains Billie Eilish's Comments on ICE, Offers ICE Commentary as Exhibit A of Celebrity Sound Bite Politics

Voir tout ACCESSWIRE

EQS Group

Publié le 04/02/2026 à 20:54, il y a 3 heures 43 minutes

Elmos Semiconductor SE is planning to distribute 36 million Euro to shareholders for the fiscal year 2025
Publié le 04/02/2026 à 20:36, il y a 4 heures 1 minute

EQS-Adhoc: Elmos Semiconductor SE approves share buyback program via the stock exchange of 10 million Euro and dividend proposal of 1.50 Euro per share for fiscal year 2025
Publié le 04/02/2026 à 20:00, il y a 4 heures 37 minutes

Belgium's Ingmar De Vos elected to Executive Board of International Olympic Committee
Publié le 04/02/2026 à 18:55, il y a 5 heures 42 minutes

Funding Circle Holdings plc: POS-Transaction in Own Shares
Publié le 04/02/2026 à 18:40, il y a 5 heures 57 minutes

Robin Zeng: Unlocking the Sustainable Energy Era with Zero-Carbon Technology